
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high prices for its blockbuster drugs Ozempic and Wegovy. While testifying before the Senate Committee on Health, Education, Labor and Pensions, Jørgensen shifted the blame for those prices to pharmacy benefits managers (PBMs),… read on > read on >